INTRODUCTION
Matrix metalloproteinases (MMP) are members of an enzyme family the extent of whose involvement in physiological and pathological situations is just beginning to be appreciated. A case in point is the vast array of normal and exacerbated immunological responses involving T cell recruitment to a particular site in the organism through the extracellular matrix (ECM) . In order to penetrate and migrate through the ECM, T cells need to lyse their way through a variety of connective tissue proteins. We review herein the available evidence for a role of MMPs secreted by T cells to allow them to migrate. We will then examine the data indicating that MMPs are not solely secreted by migrating T cells but that adjacent stromal cells also do their part, Finally, we will review a number of instances where MMP dysregulation is associated with some important T-cell dependent pathologies.
EXPRESSION OF MMP BY T CELLS WILL DICTATE THEIR CAPACITY TO MIGRATE THROUGH EXTRACELLULAR MATRIX
MMPs are zinc-dependent enzymes and include collagenases, gelatinases A and B, the stromelysins, matrylisins, metalloelastase, and the membrane-type metalloproteinases (Massova et al., 1998) . Most of the members of the MMP family are secreted by cells into the extracellular space; nonetheless, some membrane-type MMPs (MT-MMP) attached to the cell surface have also been described (Sato et al., 1994 , Strongin et al., 1995 , Matsumoto et al., 1997 , Shofuda et al., 1997 , Pei, 1999 , and shown, like their secreted counterparts, to participate in the enzymatic cascade that leads to the degradation of proteins of the ECM.
Circulating T cells in a resting state express a very limited repertoire of MMPs. Constitutive expression of only MT1-MMP, MMP-2, and MMP-9 have been reported to be expressed in resting T cells (Weeks et al., 1993 , Leppert et al., 1995 , Graesser et al., 1998 (Aoudjit et al., 1998) . In this particular case, the binding to ICAM-1 was essential but not sufficient to induce MMP-9 in T lymphoma cells. In other models, however, signaling via integrins alone was sufficient to induce MMP genes, as VCAM-l-induced the expression of MMP-1 in T cells (Leppert et al., 1995) . Romanic et al. (1994) (Weeks et al., 1993 , Zhou et al., 1993 , Conca and Wilmroth, 1994 , Aoudjit et al., 1997 , Wilmroth et al., 1998 (Pyke et al., 1992 , Basset et al., 1997 . In some cases, the expression of MMP-9 was exclusively found in the stroma surrounding the tumors (Karelina et al., 1993) . In was indeed shown that contact with several types of tumor cells in vitro induced expression of MMP-9 in fibroblasts (Himelstein et al., 1994 , Miyagi et al., 1995 , Aoudjit et al., 1997 , and a new member of the MMP family, stromelysin-3, was identified specifically in stromal cells surrounding invasive breast carcinomas (Basset et al., 1990) .
Fibroblasts surrounding human breast carcinoma cells have also been implicated in invasion and/or metastasis through the production of MT-MMP, which is thought to facilitate, via activation of MMP-2, the transition of human breast carcinoma cells from a fibroblast-like phenotype to an epithelial-mesenchymal tumorigenic state (Gilles et al., 1997) . The importance of MMP production by stromal cells was further emphasized by the same group who showed, using a co-implantation assay, that fibroblasts of stromelysin-3-deficien mice had lost the capacity to pro-mote implantation of MCF-7 human malignant epithelial cells in nude mice (Masson et al., 1998 TIMP-4-specific transcripts are expressed abundantly in the heart, moderately in tissues such as kidneys, colon, testis, ovary, and skeletal muscles, and not at all in the thymus and the spleen (Greene et al., 1996 , Leco et al., 1997 . Abundant transcripts encoding TIMP-3 were also detected in kidneys, lungs, and brain, but not in lymphoid tissues. In contrast to TIMP-2 and TIMP-4, however, TIMP-3, like TIMP-1, is encoded by an inducible gene, most notably upon exposure to T cell-dependent factors, as its expression is stimulated by AP-1 and NF-kB activators, by 12-O-tetradecanoylphorbol-13-acetate, and by TNF (Sun et al, 1995) . The consequences of T cell-induced modulation of TIMP secretion often vary according to the T cell factor implicated arid the target cells; no systematic study, however, has been done and only anecdotal data are available. For instance, whereas TIMP-1 is upregulated in monocytes, synoviocytes, uterine cervical fibroblasts, endothelial cells, and lung fibroblasts upon exposure to IL-1 or IL-6, the same TIMP-1 is downregulated when bronchial epithelial cells are treated with TNFo (Yao et al., 1997) . Decreased TIMP-3 secretion in synovial lining cells has also been reported upon exposure to Oncostatin M (Gatsios et al., 1996) . The decrease in TIMP expression or the increase in MMP production will thus necessarily tip the balance in favor of enhanced metalloproteinase activity, leading to ECM turnover, and tissue remodeling.
Like other proteins, TIMP:MMP complexes formed in the extracellular space are sensitive to proteolysis by extracellular proteases; moreover, in some cases, partial proteolysis of the complex can free TIMP from the complex, release active MMP, and shift the balance toward ECM proteolysis. One of the most potent enzymes for carrying out this task is the neutrophil elastase (NE), a protease which is abundantly secreted following massive neutrophil infiltration. NE can degrade into small fragments the inhibitory TIMP-1 molecule (Okada et al., 1988) , even if it is bound to MMP-9, thereby freeing MMP-9 and shifting the balance toward ECM proteolysis (Itoh et al., 1995) . NE is not normally expressed in T cells, although elastolytic activity has been reported to be associated with the T cell receptor complex in some T cell lines (Bristow and Flood, 1993 ) and malignant T cell lymphomas (Kossakowska et al., 1998) . To further complicate matter, NE can indirectly induce MMP secretion by T cells and stromal cells since fragmentation of ECM proteins, such as laminin, exposes TNFo binding sites on these fragments. This not only serves to restrict TNFo to sites adjacent to the inflammation, but possibly induce MMP secretion via binding of CD4-positive T cells to these templates (Hershkoviz et al., 1995) . Given (Hua and Muschel, 1996; Wang et al., 1997; Seghal et al., 1998 , Valente et al., 1998 (Powell et al., 1993; Bernhardt et al., 1994; Tsunezuka et al., 1996) . The expression of TIMPs in transgenic mice has also been shown to exert a suppressive effect on metastasizing tumor, most notably in the case of brain fibrosarcoma (Kruger A, et al., 1998) , and lymphoma (Kruger et (Bever and Garver, 1995 . Other MMPs, such as matrilysin (MMP-7) can also degrade MBP;
indeed an injection of MMP-7 and MMP-9 into the brain parenchyma induces loss of myelin integrity (Anthony et al., 1998) . Cathepsins are also capable of degrading MBR thereby contributing to the release of potential MBP auto-antigens (Cao et al., 1999) . The efficacy of IFN[ treatment in MS patients may be in part due to the ability of this drug to decrease MMP-9 activity, leading to a reduction of T-lymphocyte infiltration into the CNS , Stuve et al., 1996 .
Selective inhibition of MMPs could be a useful approach to counter the progression of autoimmune degenerative disorders where extensive tissue remodeling is present. There is an increasing number of ongoing clinical trials focusing on the potential benefit of MMP inhibitors (Parsons SL, et al. 1997 , Beattie GJ, et al. 1998 , Bramhall SR, 1998 , Wojtowicz-Praga Set al., 1998 , Brown PD, 1999 , Primrose JN et al., 1999 . These trials have so far been restricted mostly to the field of cancer, where MMPs have been shown to favor angiogenesis and confer invasive behavior to metastatic cells . However, with a better understanding of the role of MMPs in the immune response and disorders, it is likely that MMP inhibitors will be used in the treatment of chronic autoimmune disorders where ongoing proteolysis and degenerative tissue remodeling occur.
